Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity

Giuseppe Palma, Vincenzo De Laurenzi, Margot De Marco, Antonio Barbieri, Antonella Petrillo, Maria Caterina Turco, Claudio Arra

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Dendritic cells (DCs) are immunological sentinels of the organism acting as antigen-presenting cells (APC) and are critical for induction of innate and adaptive immunity. Traditionally they are divided in myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the capacity to produce large amounts of type I interferons (IFNs) in response to pathogenic agents or danger signals. It has been demonstrated that pDCs can coordinate events during the course of viral infections, allergic and autoimmune diseases and cancer. Through the production of type I IFNs, pDCs initiate protective immunity by activating classical DCs, T cells, natural killer cells and B cells. Upon activation, pDCs also differentiate into mature DCs and may contribute to the contraction of T-cell response. Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a signaling adapter to activate a prominent immune-receptor tyrosine-based activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR response by pDCs during viral infections and likely participates in pDCs tumor crosstalk. Moreover these cells seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Despite the fact that their function within a tumor context is still controversial they represent an attractive target for therapeutic manipulation of the immune system to elicit a powerful immune response against tumor antigens in combination with other therapies.

Original languageEnglish
Pages (from-to)407-414
Number of pages8
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1826
Issue number2
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Dendritic Cells
Immunity
Virus Diseases
Therapeutics
Interferon Type I
Autoimmune Diseases
Immunoreceptor Tyrosine-Based Activation Motif
Toll-Like Receptor 7
T-Lymphocytes
Neoplasms
Toll-Like Receptors
Adaptive Immunity
Neoplasm Antigens
Antigen-Presenting Cells
Myeloid Cells
Pathologic Processes
Mesenchymal Stromal Cells
Psoriasis
Innate Immunity
Natural Killer Cells

Keywords

  • Cancer
  • Clinical trial
  • Immunology
  • Plasmacytoid dendritic cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity. / Palma, Giuseppe; De Laurenzi, Vincenzo; De Marco, Margot; Barbieri, Antonio; Petrillo, Antonella; Turco, Maria Caterina; Arra, Claudio.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1826, No. 2, 12.2012, p. 407-414.

Research output: Contribution to journalArticle

@article{1009f72804d544f28069854d67c94a4b,
title = "Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity",
abstract = "Dendritic cells (DCs) are immunological sentinels of the organism acting as antigen-presenting cells (APC) and are critical for induction of innate and adaptive immunity. Traditionally they are divided in myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the capacity to produce large amounts of type I interferons (IFNs) in response to pathogenic agents or danger signals. It has been demonstrated that pDCs can coordinate events during the course of viral infections, allergic and autoimmune diseases and cancer. Through the production of type I IFNs, pDCs initiate protective immunity by activating classical DCs, T cells, natural killer cells and B cells. Upon activation, pDCs also differentiate into mature DCs and may contribute to the contraction of T-cell response. Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a signaling adapter to activate a prominent immune-receptor tyrosine-based activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR response by pDCs during viral infections and likely participates in pDCs tumor crosstalk. Moreover these cells seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Despite the fact that their function within a tumor context is still controversial they represent an attractive target for therapeutic manipulation of the immune system to elicit a powerful immune response against tumor antigens in combination with other therapies.",
keywords = "Cancer, Clinical trial, Immunology, Plasmacytoid dendritic cells",
author = "Giuseppe Palma and {De Laurenzi}, Vincenzo and {De Marco}, Margot and Antonio Barbieri and Antonella Petrillo and Turco, {Maria Caterina} and Claudio Arra",
year = "2012",
month = "12",
doi = "10.1016/j.bbcan.2012.04.007",
language = "English",
volume = "1826",
pages = "407--414",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity

AU - Palma, Giuseppe

AU - De Laurenzi, Vincenzo

AU - De Marco, Margot

AU - Barbieri, Antonio

AU - Petrillo, Antonella

AU - Turco, Maria Caterina

AU - Arra, Claudio

PY - 2012/12

Y1 - 2012/12

N2 - Dendritic cells (DCs) are immunological sentinels of the organism acting as antigen-presenting cells (APC) and are critical for induction of innate and adaptive immunity. Traditionally they are divided in myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the capacity to produce large amounts of type I interferons (IFNs) in response to pathogenic agents or danger signals. It has been demonstrated that pDCs can coordinate events during the course of viral infections, allergic and autoimmune diseases and cancer. Through the production of type I IFNs, pDCs initiate protective immunity by activating classical DCs, T cells, natural killer cells and B cells. Upon activation, pDCs also differentiate into mature DCs and may contribute to the contraction of T-cell response. Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a signaling adapter to activate a prominent immune-receptor tyrosine-based activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR response by pDCs during viral infections and likely participates in pDCs tumor crosstalk. Moreover these cells seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Despite the fact that their function within a tumor context is still controversial they represent an attractive target for therapeutic manipulation of the immune system to elicit a powerful immune response against tumor antigens in combination with other therapies.

AB - Dendritic cells (DCs) are immunological sentinels of the organism acting as antigen-presenting cells (APC) and are critical for induction of innate and adaptive immunity. Traditionally they are divided in myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the capacity to produce large amounts of type I interferons (IFNs) in response to pathogenic agents or danger signals. It has been demonstrated that pDCs can coordinate events during the course of viral infections, allergic and autoimmune diseases and cancer. Through the production of type I IFNs, pDCs initiate protective immunity by activating classical DCs, T cells, natural killer cells and B cells. Upon activation, pDCs also differentiate into mature DCs and may contribute to the contraction of T-cell response. Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a signaling adapter to activate a prominent immune-receptor tyrosine-based activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR response by pDCs during viral infections and likely participates in pDCs tumor crosstalk. Moreover these cells seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Despite the fact that their function within a tumor context is still controversial they represent an attractive target for therapeutic manipulation of the immune system to elicit a powerful immune response against tumor antigens in combination with other therapies.

KW - Cancer

KW - Clinical trial

KW - Immunology

KW - Plasmacytoid dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=84864409767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864409767&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2012.04.007

DO - 10.1016/j.bbcan.2012.04.007

M3 - Article

C2 - 22579960

AN - SCOPUS:84864409767

VL - 1826

SP - 407

EP - 414

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 2

ER -